omniture
基石药业 CSTONE PHARMACEUTICALS

Latest News

CStone announces first patient dosed in China for Phase I/II registrational bridging trial of avapritinib in advanced GIST

SUZHOU, China, Aug. 26, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today an...

2019-08-26 11:21 1428

CStone announces data from trials of CS1001, CS1002 and CS1003 to be released for the first time at 2019 CSCO Annual Meeting

SUZHOU, China, Aug. 23, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKE...

2019-08-23 11:26 1695

CStone completes registration filing for the Phase I trial of CDK4/6 inhibitor CS3002 in Australia and will soon initiate the study

SUZHOU, China, Aug. 23, 2019 /PRNewswire/ --  CStone Pharmaceuticals ("CStone" or the "Company", HK...

2019-08-23 11:20 1170

CStone submits an abstract on CS1001-201 trial to 2019 ASH Annual Meeting

SUZHOU, China, Aug. 20, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today an...

2019-08-20 10:18 3686

Abstract on CStone's CS1001-101 trial accepted for poster presentation at ESMO 2019 Annual Congress

SUZHOU, China, Aug. 19, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today an...

2019-08-19 13:50 4014

CStone Pharmaceuticals Reports First Half 2019 Financial Results

SHANGHAI, Aug. 15, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616), a leading bi...

2019-08-15 15:31 5150

CStone announces first patient dosed in China with BLU-667 for the global Phase I registrational study

SUZHOU, China, Aug. 13, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today an...

2019-08-13 12:21 6178

CStone to Build Global R&D Headquarters and Industrialization Base in the Suzhou Industrial Park

SUZHOU, China, Aug. 7, 2019 /PRNewswire/ -- The signing ceremony for CStone Pharmaceuticals' ("CSto...

2019-08-07 14:47 6946

CStone receives approval in China to initiate ivosidenib Phase I bridging registrational study for the treatment of IDH1 mutant relapsed or refractory AML

SUZHOU, China, July 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) announce...

2019-07-22 12:17 6473

CStone announces first patient dosed in China with avapritinib in global Phase III clinical trial in advanced GIST

SUZHOU, China, July 9, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today ann...

2019-07-10 10:23 6776

CStone and Bayer announce global collaboration to evaluate PD-L1 monoclonal antibody CS1001 in combination with regorafenib

SUZHOU, China, June 9, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) today ann...

2019-06-10 09:30 6610

CStone received approval to initiate clinical development in China of CS1001 and BLU-554 (CS3008) in combination therapy for HCC

SUZHOU, China, June 5, 2019 /PRNewswire/ -- CStone Pharmaceuticals (CStone; HKEX: 2616) announced t...

2019-06-05 19:56 6483

CStone submits new drug application for TIBSOVO(R) in Taiwan for the treatment of relapsed/refractory AML

HONG KONG, June 2, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) announced tha...

2019-06-03 11:45 5055

Cstone partner Agios Announces the Phase 3 ClarIDHy Trial of TIBSOVO (ivosidenib) Achieved its Primary Endpoint

SUZHOU, China, May 23, 2019 /PRNewswire/ -- The partner of CStone Pharmaceuticals ("Cstone"; HKEX:2...

2019-05-23 18:36 2010

CStone and Numab announce exclusive regional licensing agreement for ND021, a multi-functional drug candidate and potential next-generation immunotherapy

SUZHOU, China and ZURICH, May 2, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616)...

2019-05-02 11:05 1731

First patient dosed in Phase III GEMSTONE-303 study for CS1001 in combination with chemotherapy in first-line gastric adenocarcinoma and gastro-esophageal junction adenocarcinoma

SHANGHAI, April 16, 2019 /PRNewswire/ -- CStone Pharmaceuticals (the "Company" or "CStone"; HKEX: 2...

2019-04-16 16:58 5713

CStone received IND approval in China for avapritinib Phase I/II bridging registrational study in patients with advanced gastrointestinal stromal tumors

SHANGHAI, April 15, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) announced to...

2019-04-15 14:32 5264

CStone Pharmaceuticals presented poster of pre-clinical result for CS1003 at AACR

SHANGHAI, April 4, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX:2616) delivered a po...

2019-04-04 23:44 5862

CStone appoints three distinguished oncology leaders Drs. Paul A. Bunn, Jr., Elizabeth M. Jaffee and Richard S. Finn to its Scientific Advisory Board

SHANGHAI, March 25, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) is pleased t...

2019-03-25 15:14 2891

CStone receives approval in China to initiate Phase 1 clinical trial for RET inhibitor BLU-667 (CS3009)

SUZHOU, China, March 21, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) today a...

2019-03-21 21:32 4959
123